MDC Press Release | Muscular Dystrophy Canada calls on provincial governments to prioritize persons affected by neuromuscular disorders for COVID-19 vaccine
Muscular Dystrophy Canada (MDC) have released a statement regarding Canada’s vaccine roll-out plan and the neuromuscular community. MDC advocates that provincial governments prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.
February 23, 2021 – Many people living with neuromuscular disorders (NMD) are at greater risk of developing serious symptoms and complications as a result of COVID-19 due to their often pre-existing cardiac and respiratory issues and chronic comorbidities. As the voice of the NMD community in Canada, Muscular Dystrophy Canada (MDC) is calling on governments to prioritize people living with hereditary and acquired neuromuscular disorders in their vaccination roll-out.
“We want governments to recognize the critical need of the NMD community, to ensure that persons with NMDs are specifically noted as high-risk in roll out plans and prioritize their health, just as we do.”
Stacey Lintern, CEO, Muscular Dystrophy Canada.
Read the Full Release Here
Read next...
Announcing the 2026 NMD4C Award Recipients
We are excited to announce the recipients of the 2026 NMD4C Awards, recognizing excellence, leadership, and impact across Canada’s neuromuscular research community. In this fourth cycle, the program introduces two new award categories, and expand on our ability to celebrate the work of contributions of trainees and patient partners who strengthen our national network.
Expanding Our Impact: NMD4C BSTC Launches New Subcommittees and Welcomes New Members
We are so excited to introduce the new members of the NMD4C Basic Science Trainee Committee! This enthusiastic group of researchers from across the country is stepping up to contribute to some of our most important initiatives for trainees.
